- Home
- CBUS vs IMUX Comparison
CBUS vs IMUX Comparison
Compare CBUS & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBUS
- IMUX
- Stock Information
- Founded
- CBUS 2010
- IMUX 2016
- Country
- CBUS United States
- IMUX United States
- Employees
- CBUS N/A
- IMUX N/A
- Industry
- CBUS Agricultural Chemicals
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- CBUS Industrials
- IMUX Health Care
- Exchange
- CBUS Nasdaq
- IMUX Nasdaq
- Market Cap
- CBUS 65.3M
- IMUX 67.1M
- IPO Year
- CBUS 2017
- IMUX N/A
- Fundamental
- Price
- CBUS $1.50
- IMUX $0.72
- Analyst Decision
- CBUS Strong Buy
- IMUX Strong Buy
- Analyst Count
- CBUS 3
- IMUX 6
- Target Price
- CBUS $22.00
- IMUX $11.60
- AVG Volume (30 Days)
- CBUS 709.5K
- IMUX 2.4M
- Earning Date
- CBUS 08-07-2025
- IMUX 08-07-2025
- Dividend Yield
- CBUS N/A
- IMUX N/A
- EPS Growth
- CBUS N/A
- IMUX N/A
- EPS
- CBUS N/A
- IMUX N/A
- Revenue
- CBUS $4,751,000.00
- IMUX N/A
- Revenue This Year
- CBUS $32.97
- IMUX N/A
- Revenue Next Year
- CBUS $66.40
- IMUX N/A
- P/E Ratio
- CBUS N/A
- IMUX N/A
- Revenue Growth
- CBUS 104.78
- IMUX N/A
- 52 Week Low
- CBUS $1.40
- IMUX $0.56
- 52 Week High
- CBUS $10.77
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- CBUS 37.01
- IMUX 36.47
- Support Level
- CBUS $1.40
- IMUX $0.71
- Resistance Level
- CBUS $1.58
- IMUX $0.91
- Average True Range (ATR)
- CBUS 0.22
- IMUX 0.07
- MACD
- CBUS -0.09
- IMUX 0.00
- Stochastic Oscillator
- CBUS 5.43
- IMUX 29.20
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.